首页> 美国卫生研究院文献>The British Journal of Venereal Diseases >Preliminary evaluation of Clearview Chlamydia for the rapid detection of chlamydial antigen in cervical secretions.
【2h】

Preliminary evaluation of Clearview Chlamydia for the rapid detection of chlamydial antigen in cervical secretions.

机译:对 Clearview衣原体进行快速评估以快速检测宫颈分泌物中的衣原体抗原。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clearview Chlamydia (Unipath) is a rapid monoclonal antibody based latex immunodiffusion test for detecting chlamydial antigen in endocervical specimens. The assay does not require specialised equipment or extensive training and takes less than 30 minutes from sample to results. The clinical performance of Clearview Chlamydia was evaluated with 478 paired endocervical swabs from patients attending a genitourinary medicine clinic. In the first part of the study, 221 non-randomised specimens were tested by cell culture (1st swab) and Clearview (2nd swab) whereas in the second part of the study 257 randomised swabs were examined by Clearview, cell culture and immunofluorescence. The overall prevalence of chlamydial infection was 8.8% and the sensitivity, specificity, positive and negative predictive values for Clearview were 85.7%, 99.1%, 90% and 98.6%. The test requires further evaluation to establish its role in the management and control of chlamydial infection.
机译:Clearview衣原体(Unipath)是一种基于单克隆抗体的快速乳胶免疫扩散试验,用于检测宫颈内标本中的衣原体抗原。该测定不需要专门的设备或广泛的培训,并且从样品到结果只需不到30分钟。用来自泌尿生殖医学诊所的患者的478对配对的子宫颈拭子评估了Clearview衣原体的临床表现。在研究的第一部分,通过细胞培养(第一个拭子)和Clearview(第二个拭子)测试了221个非随机标本,而在研究的第二部分,通过Clearview,细胞培养和免疫荧光检查了257个随机拭子。衣原体感染的总体患病率为8.8%,Clearview的敏感性,特异性,阳性和阴性预测值分别为85.7%,99.1%,90%和98.6%。该测试需要进一步评估,以确定其在衣原体感染管理和控制中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号